Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Colombo

Showing results (321-330 of 372) with videos related to

Pageof 38
Sort By:
Gut|August 4, 2012
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BPietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, et al.
Journal of Hepatology|January 17, 2012
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2aVincent Rijckborst, Bettina E Hansen, Peter Ferenci, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2022
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairmentMark Sulkowski, Laura E Telep, Massimo Colombo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2013
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasoundMarzia Galassi, Massimo Iavarone, Sandro Rossi, et al.
Seminars in Liver Disease|July 10, 2018
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational ConsiderationsJeffrey V Lazarus, Kelly Safreed-Harmon, Mark R Thursz, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2021
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic ResponseZobair M Younossi, Andrei Racila, Andrew Muir, et al.
Hepatology Communications|March 8, 2021
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCCRoniel Cabrera, Amit G Singal, Massimo Colombo, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
Pageof 38

Showing results (321-330 of 372) with videos related to

Sort By:
Pageof 38
Gut|August 4, 2012
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BPietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, et al.
Journal of Hepatology|January 17, 2012
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2aVincent Rijckborst, Bettina E Hansen, Peter Ferenci, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2022
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairmentMark Sulkowski, Laura E Telep, Massimo Colombo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2013
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasoundMarzia Galassi, Massimo Iavarone, Sandro Rossi, et al.
Seminars in Liver Disease|July 10, 2018
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational ConsiderationsJeffrey V Lazarus, Kelly Safreed-Harmon, Mark R Thursz, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2021
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic ResponseZobair M Younossi, Andrei Racila, Andrew Muir, et al.
Hepatology Communications|March 8, 2021
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCCRoniel Cabrera, Amit G Singal, Massimo Colombo, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
Pageof 38